The A-HeFT (African American Heart Failure Trial) showed that isosorbide/hydralazine was associated with significant reductions in mortality in African Americans with heart failure compared with placebo. The results of a recently published genetic substudy identified a gene variant related to nitric oxide synthase production that attributed to the treatment response observed in patients enrolled in the A-HeFT. This finding suggests that isosorbide/hydralazine's ability to improve heart failure outcomes is tied to a genetic trait that may be more prevalent in African Americans than whites, but is not necessarily related to perceived race.
Institute of Medicine: unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press, 2002.
2.
DriesDLExnerDVGershBJCooperHACarsonPEDomanskiMJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med1999;340:609–16.
3.
CohnJNArchibaldDGZiescheS. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med1986;314:1547–52.
4.
FletcherRDCintronGBJohnsonGOrndorffJCarsonPCohnJN. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation1993;87(6 suppl):VI49–55.
5.
ExnerDVDriesDLDomanskiMJCohnJN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med2001;344:1351–7.
6.
TaylorALZiescheSYancyC. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med2004;351:2049–57.
7.
McNamaraDMTamSWSabolinskiML. The genetic risk-assessment substudy of the African-American Heart Failure Trial (A-HeFT): impact of genetic variation of NOS3 (abstract 232). Presented at: Heart Failure Society of America 2005 Annual Scientific Meeting, Boca Raton, FL, September 18–21, 2005.
8.
McNamaraDMHolubkovRPostavaL. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation2003;107:1598–602.
9.
PhilipIPlantefeveGVuillaumier-Barrot. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation1999;99:3096–8.
